FDA Panel Rejects Lipocine's Testosterone Pill Post author:Sam Post published:January 10, 2018 Post category:BioPharma The FDA voted six in favor and thirteen against the benefit/risk profile of TLANDO. Source: BioSpace You Might Also Like FDA Calls Omeros' Kidney Disorder Drug a Breakthrough June 12, 2017 Scandal-Ridden INSYS Replaced 90% of Its Original Sales Force in Makeover October 8, 2017 This Booming Biotech Inks Huge Lease in the East Bay May 2, 2017
